he goal this clinical trail is to evaluate the safety、Pharmacokinetic and immunogenicity of GR2303 injection。 Subjects will be enrolled in different groups in sequential order, and within each group will be randomly assigned to receive either GR2303 injection or placebo administration, with each Subjects will be enrolled in only one of these groups
Healthy adult subjects
Signed informed consent
History or presence of any clinically significant organ system disease that could interfere with the objectives of the study or the safety of the subjects.
Prior use of drug targeting TNF-like cytokine 1A
history of malignant tumor
psitive results for Hepatitis B surface antigen (HBsAg), anti Hepatitis C antibody (HCV Ab) or human immunodeficiency virus (HIV)
8
Treatment groupsSee each treatment group below.